Find Academic Supervisors

• Tumor microenvironment
• Macrophage biology
• Hypoxia inducible factor (HIF) biology
• +6 more

Dr. Timothy Eubank is a Professor in the Department of Microbiology, Immunology & Cell Biology at West Virginia University School of Medicine. He also serves as a Senior Advisor at the WVU Health Sciences Center in the Department of Research & Graduate Education and is a Member of the WVU Cancer Institute Research Programs. Dr. Eubank's research focuses on the role of myeloid cells and mononuclear phagocytes in tumor growth and angiogenesis, with particular expertise in monocyte and macrophage HIF (hypoxia inducible factor) biology. His lab has made several groundbreaking discoveries, including being the first to report that GM-CSF stimulates tumor macrophages to overexpress soluble VEGFR-1, which sequesters tumor-produced VEGF, and the first to identify the disparate functions of HIF-1α and HIF-2α in tumor-associated macrophages, discovering that HIF-2α can be anti-angiogenic. Analysis of Dr. Eubank's recent publications reveals a strong focus on tumor microenvironment, particularly examining macrophage subsets in breast and pancreatic cancers using advanced Electron Paramagnetic Resonance (EPR) imaging techniques. His work spans multiple disciplines including cancer biology, immunology, biomedical engineering, and molecular imaging, with a consistent theme of understanding how tumor hypoxia and immune cell interactions drive cancer progression. K99/R00 Pathway to Independence Award from the National Cancer Institute Dr. Eubank's research is supported by multiple collaborations across WVU, working with colleagues in Biochemistry, Pharmaceutical Sciences, Radiology, and Surgery to develop novel molecular probes for in vivo measurement of tumor oxygenation, pH, and inorganic phosphate. His lab's work on understanding how different macrophage HIFs regulate chemotherapy success in breast cancer models has significant implications for improving cancer treatment efficacy. Dr. Eubank's lab occupies spaces 5612, 5608, 5607, and 5602 in the Health Sciences South building, where his team conducts research on the 'In vivo Multifunctional Magnetic Resonance Research' program, investigating the origin and role of macrophages that initiate and maintain treatment resistance in breast and pancreatic cancers.

• Liver Transcriptional Regulation
• Nuclear Receptor Signaling
• Cancer Promotion Mechanisms
• +4 more

Joseph Locker, MD, PhD is Professor of Pathology at the University of Pittsburgh School of Medicine, with dual appointments in the Division of Experimental Pathology and Division of Molecular & Genomic Pathology. His research integrates basic transcriptional mechanisms with clinical pathology, focusing on liver disease processes. Dr. Locker's research interests center on liver transcriptional regulation , specifically examining how nuclear receptors like CAR and HNF4 control hepatocyte proliferation and metabolic functions. His work distinguishes cancer-promoting hyperplasia from natural regeneration processes, and investigates transcriptional deregulation in cirrhosis. Current projects utilize NextGen sequencing methodologies for genome-wide characterization of gene expression and chromatin remodeling. His publication record shows consistent productivity from the 1970s through 2025, with recent work spanning liver disease mechanisms, cancer biology, and molecular diagnostics. Research trends indicate increasing integration of genomic methodologies with traditional pathological analysis. As an active NIH-funded investigator, Dr. Locker maintains laboratory operations focused on translational research bridging molecular mechanisms with clinical applications in liver disease. His work provides fundamental insights into transcriptional control of liver regeneration and cancer promotion, with potential therapeutic implications for cirrhosis and hepatocellular carcinoma. Dr. Locker's clinical expertise includes molecular diagnostics, analysis of mutations and translocations, anatomic pathology, and immunohistochemistry. His dual MD/PhD training enables effective translation of basic research findings into clinical applications.

Ralph RuppView profile

Professor

• Developmental Biology
• Epigenetics
• Chromatin Structure and Dynamics
• +7 more

Prof. Dr. Ralph Rupp is a Professor of Molecular Biology at the Faculty of Medicine, Ludwig Maximilian University of Munich, where he leads the Developmental Epigenetics research group at the Biomedical Center. His laboratory investigates the role of chromatin structure and histone modifications in regulating embryonic development, primarily using the African clawed frog (Xenopus) as a model system. Dr. Rupp's research focuses on stage-specific histone modification profiles during embryogenesis and how these epigenetic landscapes regulate cellular plasticity and differentiation. His group has made seminal contributions to understanding how histone modifications like H4K20 methylation and chromatin remodeling complexes such as Brg1 control key developmental transitions. The lab combines embryological approaches with molecular and biochemical techniques to study how chromatin maturation constrains cellular potency during development. His recent publications demonstrate consistent output in high-impact journals including Cell Systems, Developmental Cell, and Nucleic Acids Research, with research themes spanning histone modification dynamics, chromatin remodeling in embryonic patterning, and transcriptome analysis of differentiation processes. The work shows particular strength in bridging molecular epigenetics with developmental biology. Scientific recognition includes: Ausbildungsstipendium der DFG (1991-1992) Postdoctoral Fellowship of the American Muscular Dystrophy Association (1993) Team Grant Coordinator for the Human Frontier Science Program (1999-2003) Prof. Rupp currently leads Project A12 within the CRC 1064 research consortium and advises PhD students including Janet Tait. His lab maintains active collaborations within the Biomedical Center and participates in graduate training programs. The research group continues to advance our understanding of how epigenetic mechanisms guide vertebrate development from pluripotent embryonic cells to differentiated somatic lineages.

Robert SchneiderView profile

Professor

• Epigenetics
• Chromatin Biology
• Metabolism-Epigenetics Crosstalk
• +4 more

Prof. Robert Schneider serves as Professor at Ludwig-Maximilians-Universität München's Faculty of Biology and Director of the Institute of Functional Epigenetics at Helmholtz Zentrum München. He leads Project A20 within the Collaborative Research Center 1064, investigating how metabolic enzymes and their products regulate chromatin dynamics and gene expression. His dual appointments position him at the nexus of academic research and translational biomedical science in Munich's vibrant research ecosystem. His academic journey began with Biology Diploma studies (1990-1996) and doctoral research (1996) at LMU Munich under Prof. Regine Kahmann. This was followed by an EMBO fellowship at Cambridge's Gurdon Institute (2000-2004), a Max Planck Research Group leadership in Freiburg (2005-2012), and Director de Recherche position at Strasbourg's IGBMC (2012-2016) before his current roles. Research focuses on metabolite-chromatin crosstalk, particularly how short-chain acyl-CoAs drive histone lysine acylations to reprogram gene expression. The lab employs innovative approaches including metabolic enzyme recruitment to specific genes, in vitro chromatin reconstitutions, and single-cell tracing of transcriptional memory. Current work emphasizes RNA modification enzymes (e.g., METTL5/6) in pluripotency and the role of sugar metabolism in epigenetic inheritance. This research provides fundamental insights into how nutrition and metabolism shape genomic regulation with implications for cancer and developmental disorders. Recent publications (2017-2020) reveal a strategic expansion from histone modifications into RNA epigenetics and single-cell dynamics of metabolic-epigenetic interactions. The work consistently bridges biochemical mechanism with functional outcomes in stem cells and disease models, demonstrating increasing technical sophistication through integrative genomics and live-cell imaging approaches. Major recognitions include: ERC Starting Grant (2008) HFSP Career Development Award (2006) Chaire Gutenberg, University of Strasbourg (2012) Multiple labellisation awards from French research foundations (2012-2014) Epigenome Network of Excellence membership Mentorship occurs through structured PhD programs including CRC 1064's graduate initiatives and Helmholtz's doctoral training. The lab maintains active grants from DFG (CRC 1064), ERC, and collaborative consortia, supporting interdisciplinary projects that attract international talent. Prof. Schneider serves on editorial boards (PLOS Genetics) and selection committees, fostering global scientific exchange while maintaining a highly collaborative lab environment focused on mechanistic epigenetics. The Institute of Functional Epigenetics operates as a dynamic hub within Helmholtz Zentrum München, combining biochemical expertise with genomic and computational approaches. The lab's integration into CRC 1064 enables synergistic collaborations across Munich's research institutions, particularly in developing novel methods to probe metabolism-chromatin interfaces in real time.

Stefan H. StrickerView profile

Professor

• Epigenetics
• Chromatin Dynamics
• Transcriptional Reprogramming
• +6 more

Professor Stefan H. Stricker is a W2 Professor of Reprogramming and Regeneration in the Department of Physiological Genomics at the Medical Faculty of Ludwig-Maximilians-University Munich. He leads Project A35 focused on 'Functional analysis and targeted manipulation of chromatin dynamics on mammalian noncoding regions' as part of the CRC 1064 research program. His laboratory is situated within the Biomedical Center (BMC) in Martinsried, which integrates natural sciences with clinical applications to study cell development and plasticity. Professor Stricker's research focuses on epigenetic regulation and cellular reprogramming, particularly investigating how chromatin dynamics can be manipulated to enable cell fate transitions. His work bridges molecular biology with regenerative medicine applications, with significant emphasis on neural lineage development and CRISPR-based technologies for epigenome editing. Recent publications demonstrate his expertise in transcriptional engineering and overcoming epigenetic barriers during cell reprogramming processes. His selected publications from 2019-2021 reveal a strong research trajectory in epigenetics and cellular reprogramming, with articles appearing in high-impact journals including Nature Communications, Cell Stem Cell, and Physiological Reviews. These works collectively explore the intersection of CRISPR technology, epigenetic regulation, and cellular plasticity with implications for regenerative medicine. Kitty Cookson award (2013) EMBO Long-term Fellowship (2009) B.I.F. Böhringer Ingelheim Fonds Scholarship (2005) As an active member of the Graduate School for Systemic Neurosciences since 2016, Professor Stricker supervises graduate students and contributes to academic training. His laboratory benefits from collaborations through the International Training Network (ITN) Nanostem and the Helmholtz@epigenetics committee, providing students with interdisciplinary research opportunities and access to state-of-the-art core facilities at the Biomedical Center.

Maria Elena Torres-PadillaView profile

Professor

• Epigenetics
• Stem Cell Biology
• Heterochromatin formation
• +5 more

Prof. Maria Elena Torres-Padilla is Director of the Institute of Epigenetics and Stem Cells at Helmholtz Zentrum München and Professor (W3) Chair of Stem Cell Biology at the Faculty of Biology, Ludwig-Maximilians-University Munich. She also serves as Vice Chair of the CRC 1064 and holds an Honorary Professorship at the University of Aarhus Denmark. Her leadership extends to coordinating the EpiGene2Sys Network and serving on the Steering Board of Single Cell Omics Germany. Her research focuses on epigenetic mechanisms during early mammalian development, particularly: Heterochromatin formation and silencing in mouse embryos The role of pericentromeric RNA in chromatin organization Phase separation potential of heterochromatin proteins Nuclear reprogramming and cellular plasticity Genome-lamina interactions during embryonic development Prof. Torres-Padilla's recent publications demonstrate a strong focus on chromatin dynamics during early embryonic development, with particular emphasis on heterochromatin establishment and the potential role of phase separation mechanisms. Her work combines advanced genomic, transcriptomic, and imaging approaches to address fundamental questions in epigenetics. Her scientific achievements have been recognized with numerous awards: Elected EMBO Member (2015) Female Award of the German Stem Cell Network (2018) ERC Starting Grant awardee (2011) EMBO Young Investigator (2011) Selected as Extraordinary Young Scientist by the World Economic Forum (2015) Prof. Torres-Padilla maintains an active research program with significant funding support. She leads Project A24 within CRC 1064 investigating heterochromatin formation in mouse embryos. Her laboratory at the Institute of Epigenetics and Stem Cells provides training for PhD students and postdoctoral researchers, with opportunities to work on cutting-edge epigenetics research using state-of-the-art technologies. She directs the Institute of Epigenetics and Stem Cells (IES), a research group focused on understanding the epigenetic mechanisms that govern stem cell identity and early embryonic development. The institute employs advanced genomic, imaging, and biochemical approaches to investigate chromatin organization and nuclear reprogramming.

Helena Jernberg WiklundView profile

Professor

• Translational research
• Epigenetics
• Drug discovery
• +7 more

Helena Jernberg Wiklund is a Professor at Uppsala University's Department of Immunology, Genetics and Pathology within the Faculty of Medicine. She leads the Cancer Precision Medicine Research Program and serves as Director of Postgraduate Studies at Rudbeck Laboratory. Professor Jernberg Wiklund also sits on the Faculty Board at the Medical Faculty and participates in international (MMRF, IMF, AICR) and national (Barncancerfonden and Cancerfonden) grant review committees. Her research focuses on translational cancer biology with particular emphasis on multiple myeloma (MM), one of Sweden's most common blood cancers. She investigates mechanisms of survival and cell death in MM, using various model systems including cultured cells, patient tumor cells, and mouse models that accurately represent human disease. Her work aims to identify molecules essential for tumor cell survival that could be targeted to restore apoptosis and improve therapeutic outcomes. Analysis of her recent publications reveals a strong focus on epigenetic mechanisms in multiple myeloma, particularly involving EZH2, DNMTs, and lncRNA-mediated chromatin dynamics. Her research spans across molecular biology, cancer metabolism, and immunotherapy approaches, demonstrating an integrated approach to understanding and treating hematological malignancies. Professor Jernberg Wiklund actively mentors PhD students and researchers in her laboratory, contributing to the next generation of cancer researchers. She also engages in course administration, examination, and teaching at both undergraduate and postgraduate levels, while serving as a moderator and abstract coordinator for international scientific meetings.

Jean-Pierre EtchegarayView profile

Assistant Professor

• Epigenetics
• Transcriptional Regulation
• Circadian Rhythms
• +5 more

Jean-Pierre Etchegaray is an Assistant Professor in the Department of Biological Sciences at Rutgers University. His research focuses on epigenetic and transcriptional programs governing cell fate changes during development, cancer dormancy, and aging restoration. Key projects include studying TET-mediated DNA oxidation, RNA Polymerase II transcriptional pausing, and circadian rhythm modulation of cell identity. Expertise: Epigenetics, Transcription, Circadian Rhythms, Stem Cells Projects: TET enzyme biology, Transcriptional elongation, Circadian clock epigenetics Recent work investigates how DNA oxidation intermediates regulate cancer dormancy and aging, while earlier studies explored SIRT6 interactions and circadian clock mechanisms. His lab employs molecular and biochemical approaches to dissect these dynamic processes. Scientific Awards: 2019 IMRT Award 2020 Busch Biomedical Award Publications span epigenetic regulation of stem cells, cancer microenvironment interactions, and circadian rhythm biochemistry. Collaborations include multidisciplinary teams in cancer immunotherapy and aging research.

Stefan KubicekView profile

Researcher

• Chemical Epigenetics
• Chromatin Biology
• Cancer Biology
• +5 more

Stefan Kubicek is a Principal Investigator and Head of the Molecular Discovery Platform at CeMM (Center for Molecular Medicine of the Austrian Academy of Sciences). His research bridges Chemical Biology and Epigenetics , focusing on small molecules that alter cellular identity through chromatin pathways and nuclear metabolism. Previously, he led the Christian Doppler Laboratory for Chemical Epigenetics and Antiinfectives, a public-private partnership with Boehringer Ingelheim and Haplogen. MSc in Synthetic Organic Chemistry (Vienna University of Technology) PhD in Molecular Biology (Thomas Jenuwein Lab, IMP Vienna) Postdoc in Chemical Biology (Stuart Schreiber, Broad Institute) His work explores ATP-dependent chromatin remodeling in cancer and diabetes, developing chemical tools against epigenetic modifiers. Recent publications highlight nuclear metabolic targets , protein phase separation , and pancreatic cell transdifferentiation . Collaborations with pharmaceutical companies have yielded high-impact studies, including Nature Genetics (2019) on synthetic lethal cancer targets. Research Funding includes: ERC Proof of Concept Grant (ONCO-SPLICE, 2024-2026) FWF Stand-Alone Program (2024-2027) WWTF Life Sciences Grant (2022-2025) Breakthrough T1D Award (2024-2025) Lab members include Predoctoral Fellows (Sandra Goll, Andreas Reicher, Jamie Reilly, Jiri Reinis, Jonathan Shklarek), Postdoctoral Fellows (Tuan-Anh Nguyen), and technicians (Maria Ciobanu, Diana Daum). His team deploys high-throughput screening , genetic code expansion , and stochastic protein tagging to uncover nuclear metabolic-epigenetic connections.

Biswajyoti SahuView profile

Research Fellow

• Biomedical Sciences
• Cancer Biology
• Transcriptional Regulation
• +3 more

Biswajyoti Sahu is an Academy Research Fellow and Docent at the University of Helsinki, affiliated with the Doctoral Programme in Integrative Life Science and the Applied Tumor Genomics (ATG) group at Medicum. He previously served as a Visiting Scientist at the University of Cambridge (2018–2019) and the Whitehead Institute for Biomedical Research (2015). Biomedical Sciences Cancer Biology Transcriptional Regulation Epigenetics His research focuses on oncogenes, transcription factor dynamics, and epigenetic mechanisms in cancer and development. Key themes include chromatin modifier enzymes, transposable elements, and cellular reprogramming. Recent publications highlight his work on oncogene convergence pathways (2025), transposable element derepression (2025), and single-cell multiome protocols (2024). Awards include the Finnish Cultural Foundation’s Grant (2011), Endocrine Trainee Day Fellowship (2009), and multiple presentation awards.

Mattias AleniusView profile

Professor

• Molecular Neuroscience
• Olfaction
• Gustation (Taste)
• +7 more

Mattias Alenius is a full Professor at the Department of Molecular Biology , Umeå University , Sweden, where he heads an active research group investigating the molecular and cellular bases of olfaction and taste. His laboratory exploits the genetic tractability of Drosophila and the physiological relevance of mouse models to uncover conserved mechanisms that govern sensory neuron specification, ciliary trafficking, and systemic feedback control of sensory perception. Research Focus His team is particularly interested in: Homeostatic control of neuronal activity and how its failure leads to neurodegenerative diseases. Olfactory and gustatory circuits —leveraging the numerically simple and genetically powerful Drosophila system. Hedgehog signaling and its role in ciliary transport of odorant receptors across species. Inter-organ communication , including gut-to-brain signaling that modulates feeding behavior. Epigenetic inheritance , exploring how paternal diet shapes chromatin states and metabolic phenotypes in offspring. Methodologically, the group integrates in vivo genetics, single-cell transcriptomics, live-cell imaging, cryo-EM, and behavioral assays to dissect these processes from molecule to organism. Scientific Output & Trends Across more than two decades, Prof. Alenius has produced a steady stream of high-impact publications in journals such as Nature Communications , Cell Reports , PNAS , Cell , PLoS Biology , and BMC Biology . His recent work (2022-2024) increasingly centers on nutrient sensing and gut-brain taste modulation , while earlier studies laid the groundwork for understanding ciliary dynamics and transcriptional codes specifying olfactory receptor choice. Collectively, the publications reveal a trajectory from developmental specification of sensory neurons to systemic metabolic control, unified by a focus on hedgehog signaling , cilia-mediated processes , and transcriptional/epigenetic mechanisms . Labs & Teams Prof. Alenius leads the Group Mattias Alenius located in rooms 6K and 6L within the hospital area at Umeå University. The group participates in the university’s Department of Molecular Biology and collaborates extensively across neuroscience and metabolism communities both nationally and internationally. Contact Email: mattias.alenius@umu.se Phone: +46 90 786 91 57

• Bioinformatics
• Computational Biology
• Epigenetics
• +5 more

Dr. Ning Liu is a Postdoctoral Research Fellow at the South Australian Immunogenomics Cancer Institute (SAiGENCI) within the Faculty of Health and Medical Sciences at the University of Adelaide. As a bioinformatician and computational biologist, Dr. Liu specializes in developing computational tools for epigenetics and transcriptomics research, with particular expertise in next-generation sequencing data analysis including ChIP-seq, ATAC-seq, Hi-C, RNA-seq, single cell RNA-seq, and spatial transcriptomics. Dr. Liu's research focuses on developing novel computational methods to study the human genome in the context of transcriptomics and epigenomics. Currently, Dr. Liu maintains three Bioconductor software packages: standR for spatial transcriptomics analysis of GeoMx DSP data, hoodscanR for cellular neighborhood detection in spatial transcriptomics, and scider for modeling global cell density in spatial transcriptomics data. With strong emphasis on translating biological insights to medical applications, Dr. Liu's work bridges computational methodology with clinical relevance in cancer research and immunology. Dr. Liu is eligible to supervise Masters and PhD students as a Co-Supervisor, reflecting their established expertise in bioinformatics and computational biology. Their research has resulted in numerous publications focusing on spatial transcriptomics, cancer immunology, and computational tool development, with applications in understanding tumor microenvironments and immunotherapy response. Dr. Liu's scholarly contributions demonstrate a consistent focus on spatial biology methodologies applied to cancer research, particularly head and neck cancer. Their publications reveal expertise in developing computational frameworks that address technical challenges in spatial transcriptomics while providing biological insights with potential clinical applications in immunotherapy. As a research supervisor, Dr. Liu contributes to the academic community by mentoring graduate students in computational biology techniques and applications. Their work environment at the Adelaide Health and Medical Sciences building on the West End Health Precinct provides access to state-of-the-art facilities supporting their computational research in cancer immunogenomics.

Jose TeixeiraView profile

Professor

• Developmental Biology
• Genetics
• Molecular Oncology
• +3 more

Jose Teixeira is a Professor at Michigan State University's College of Human Medicine, affiliated with the Department of Obstetrics, Gynecology and Reproductive Biology. His research focuses on developmental biology and genetics, particularly in the context of gynecological disorders and cancers. Studied fibroid tumors, endometrial/ovarian cancers Investigates genetic pathways for disease progression Pioneered molecular understanding of reproductive tract development His recent publications highlight work on HMGA2 overexpression, stem cell markers like CRIP1, and epigenetic mechanisms in fibroid pathogenesis. Key trends include the intersection of developmental genetics and tumor biology, with applications in precision medicine for uterine disorders. Active in methodological advances like STORM-seq for single-cell analysis and exploring racial disparities in fibroid biology. Email: teixei15@msu.edu .

Joshua Mark BrickmanView profile

Professor

• developmental biology
• embryonic stem cells
• totipotency
• +7 more

Joshua Mark Brickman is a Professor in the Department of Biomedical Sciences at the University of Copenhagen's Faculty of Health and Medical Sciences. He leads the Brickman Group at reNEW (Novo Nordisk Foundation Center for Stem Cell Medicine), a global research center focused on stem cell medicine. His laboratory, the Brickman Lab, is located at Blegdamsvej 3B, 2200 København N, Denmark. Professor Brickman earned his B.A. in Chemistry & Philosophy from the University of Vermont in 1985, followed by a Ph.D. in Biochemistry and Molecular Biology from Harvard University in 1996. After completing his doctoral studies focusing on transcription, he pursued post-doctoral training in developmental biology, working with early mouse development and embryonic stem cells as models for understanding developmental processes. Brickman's research focuses on understanding how transcription factors regulate cell fate choice in embryonic stem cells and early embryos. His group investigates transcriptional priming and commitment in stem cells, particularly in the specification of the endoderm lineage. They aim to understand how these priming events relate to stem and progenitor cell potency. The Brickman Group explores three main research themes: the molecular biology of enhancer function, transcription factors and metabolic influence in stem cell competence, and transcriptional regulation in the endoderm lineage. Their work has led to significant innovations including the development of human hypoblast stem cells, drugs for improved organ differentiation, and new approaches to IVF culture. Professor Brickman's laboratory has received funding from prestigious sources including the European Research Council, Novo Nordisk Foundation, Danmarks Frie Forskningsfond, Lundbeck Foundation, and the BRIDGE - Translational Excellence Program. His research on FGF/ERK signaling has proposed a new paradigm for understanding transcription factor function as enablers of signaling response rather than determinants of transcription itself. The Brickman Group consists of a diverse team of approximately 28 researchers including postdocs, PhD students, research assistants, and visiting scientists. Current members include Assistant Professor Molly Lowndes, Researcher Rita S. Monteiro, Postdocs Joji Marie Yap Teves and S M Nazmus Salehin, Master Students Hanna Kreilgaard McNamara and Sarah Sølling Brendstrup, and several others working collaboratively on various aspects of stem cell biology and developmental regulation.

• Genomic Conflicts of Interest
• Mammalian Embryology
• Epigenetics
• +6 more

Mads Lerdrup is an Associate Professor at the Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, where he leads research in the Molecular Aging Program. His work focuses on understanding how mammalian organisms handle inbuilt genomic conflicts of interest, particularly during embryonic development. Education Ph.D., University of Copenhagen (2007) M.Sc., University of Copenhagen (2002) Dr. Lerdrup's research centers on the remarkable genomic environment during mammalian fertilization and early embryonic development. His laboratory investigates extensive genomic reprogramming, epigenetic mark rewriting, and retrotransposon activity during these critical stages. He has pioneered the development of single-cell and low-input genome-wide methods to study replication stress in early mammalian embryos and the factors that instruct changes in oocyte and embryo epigenomes. His work has resulted in a comprehensive software suite for genome-wide data analysis (easeq.net). His recent publications demonstrate significant contributions to understanding transcription-replication collisions, histone modifications, DNA replication in embryos, and mitochondrial dysfunction related to aging. His research spans multiple high-impact journals including Nature Communications, Nature Biotechnology, Science Advances, and Nature Genetics. Dr. Lerdrup maintains an active research network with collaborations across multiple countries and has developed a side business as founder and owner of the consulting firm genessence (2022-2025). Research Activities Establishment of new single-cell and low-input genome-wide methods Identification of causes for replication stress in the early mammalian embryo Identification of factors instructing changes in oocyte and embryo epigenomes